D. Lebwohl

发表

Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib)

W. Zhang, G. Folprecht, K. Danenberg, 2012, The Pharmacogenomics Journal.

Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia

K. Davis, S. Rives, Krysta D Schlis, 2018, The New England journal of medicine.

Herbimycin A Induces the 20 S Proteasome- and Ubiquitindependent Degradation of Receptor Tyrosine Kinases (*)

N. Rosen, D. Lebwohl, L. Sepp-Lorenzino, 1995, The Journal of Biological Chemistry.

A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line.

N. Rosen, D. Lebwohl, L. Sepp-Lorenzino, 1994, Oncogene.

Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.

C. Hudis, J. Baselga, D. Lebwohl, 1995, Seminars in oncology.

Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.

T J Yao, C. Hudis, L. Norton, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin.

A. Ullrich, T. Dull, D. Lebwohl, 1987, The Journal of biological chemistry.

Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials

A. Harris, G. Folprecht, A. Giatromanolaki, 2012, British Journal of Cancer.

Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer

L. Collette, C. Sternberg, D. Lebwohl, 2005, Oncology.

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

T. Fojo, S. Bates, A. Rutt, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen adminstration is associated with a high rate of treatment‐limiting symptoms in male breast cancer patients

D. Lebwohl, P. Borgen, T. Moredo Anelli, 1994 .

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

E. Thiele, O. Witt, P. J. Vries, 2013, The Lancet.

ffi cacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex ( EXIST-1 ) : a multicentre , randomised , placebo-controlled phase 3 trial

E. Thiele, O. Witt, P. J. Vries, 2012 .

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)

David C. Smith, D. Lebwohl, D. Vaughn, 2004, Investigational New Drugs.

Predictive Biomarkers and Personalized Medicine Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK 787 / ZK 222584 ( Vatalanib ) Antiangiogenic Therapy

A. Harris, G. Folprecht, K. Gatter, 2011 .

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

D. Kerr, J. Hainsworth, J. Hecht, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.

J. Wood, J. Pinheiro, J. Drevs, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.

J. Hennig, J. Drevs, D. Lebwohl, 2010, Anticancer research.

Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.

M. Piccart, G. Hortobagyi, J. Baselga, 2013, Journal of the National Cancer Institute.

Phase I Study of JM-216 (an Oral Platinum Analogue) in Combination with Paclitaxel in Patients with Advanced Malignancies

Suzanne F. Jones, J. Hainsworth, H. Burris, 2002, Investigational New Drugs.

Progression-Free Survival: Gaining on Overall Survival as a Gold Standard and AcceleratingDrug Development

D. Lebwohl, J. Baladi, A. Kay, 2009, Cancer journal.

Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer.

L. Norton, J. Crown, D. Lebwohl, 1993, Seminars in oncology.

Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat).

D. Lebwohl, H. Prince, M. Cooper, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).

C. Isaacs, Bing-he Xu, F. André, 2013 .

Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.

G. Hortobagyi, J. Baselga, H. Rugo, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line.

N. Rosen, D. Lebwohl, L. Sepp-Lorenzino, 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

A phase II trial of JM-216 in cervical cancer: an NCIC CTG study.

L. Seymour, H. Hirte, D. Lebwohl, 2002, Gynecologic oncology.

The T lymphocyte response to cytochrome C. III. Relationship of the fine specificity of antigen recognition to major histocompatibility complex genotype.

E. Margoliash, L. Matis, C. Hannum, 1982, Journal of immunology.

Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer.

U. Vanhoefer, D. Lebwohl, T. Trarbach, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer.

U. Vanhoefer, B. Wiedenmann, D. Lebwohl, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.

C. Hudis, L. Norton, J. Baselga, 1998, Cancer investigation.

Phase I T rial a nd P harmacokinetic S tudy o f B MS-247550, a n Epothilone B A nalog, A dministered I ntravenously o n a D aily Schedule f or F ive D ays

T. Fojo, S. Bates, A. Rutt, 2003 .

Synthesis, purification, and characterization of the cytoplasmic domain of the human insulin receptor using a baculovirus expression system.

D. Lebwohl, O. Rosen, R. Herrera, 1988, The Journal of biological chemistry.

7155 Overall survival among metastatic renal cell carcinoma (MRCC) patients corrected for crossover using a rank preserving structural failure time (RPSFT) model: analyses from the everolimus phase III trial

R. Motzer, D. Lebwohl, P. Korhonen, 2009 .

Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.

C. Hudis, L. Norton, J. Baselga, 1996, Seminars in oncology.

S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial.

M. Piccart, G. Hortobagyi, J. Baselga, 2011 .

Expression of inducible membrane-anchored insulin receptor kinase enhances deoxyglucose uptake.

D. Lebwohl, O. Rosen, M. Chan, 1991, The Journal of biological chemistry.

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy

Suzanne F. Jones, M. Piccart, H. Burris, 2009, Cancer Chemotherapy and Pharmacology.

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

E. Estey, D. Neuberg, J. Griffin, 2004 .

Clinical development of platinum complexes in cancer therapy: an historical perspective and an update.

D. Lebwohl, R. Canetta, D Lebwohl, 1998, European journal of cancer.

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

J. Hainsworth, E. Baudin, James C Yao, 2011, The Lancet.

Everolimus for advanced pancreatic neuroendocrine tumors.

E. D. de Vries, E. Van Cutsem, James C Yao, 2011, The New England journal of medicine.

CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.

M. Maitland, C. Kyratsous, D. Lebwohl, 2021, The New England journal of medicine.

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

A. Garg, M. Piccart, G. Hortobagyi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

Suzanne F. Jones, F. J. Ramos, J. Baselga, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

David Chen, Klemens Budde, K. Budde, 2013, The Lancet.

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

M. Piccart, G. Hortobagyi, J. Baselga, 2012, The New England journal of medicine.

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

M. Piccart, G. Hortobagyi, J. Baselga, 2013, Advances in Therapy.

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

D. Lebwohl, Ö. Anak, S. Saletan, 2013, Annals of the New York Academy of Sciences.

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

J. Ajani, Y. Bang, E. Van Cutsem, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients.

D. Lebwohl, P. Borgen, A. Anelli, 1994, Cancer.

Phase I Clinical and Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B, in Solid Tumors

Susan Band Horwitz, Anne Hamilton, D. Lebwohl, 2004, Clinical Cancer Research.

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.

C. Hudis, J. Crown, D. Lebwohl, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

D. Lebwohl, R. Yuan, A. Kay, 2009, Journal of hematology & oncology.

Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.

E. Van Cutsem, E. Lin, J. Hecht, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effi cacy of everolimus in advanced renal cell carcinoma : a double-blind , randomised , placebo-controlled phase III trial

C. Porta, A. Ravaud, R. Figlin, 2008 .

Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy

A. Harris, G. Folprecht, K. Gatter, 2011, Clinical Cancer Research.

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.

J. Baselga, A. Lluch, J. Tabernero, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.

M. Socinski, M. Edelman, J. Vansteenkiste, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

M. Piccart, G. Hortobagyi, J. Baselga, 2014, Advances in Therapy.

TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials

H. Lenz, C. Vigen, K. Danenberg, 2011, The Pharmacogenomics Journal.

Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial

E. Baudin, L. Kvols, P. Rougier, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.

C. Hudis, L. Norton, J. Baselga, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxol and Recombinant Human Granulocyte Colony‐Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer

C. Hudis, L. Norton, S. Arbuck, 1993, Annals of the New York Academy of Sciences.

Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition.

H. Choy, D. Carbone, G. Amorino, 1999, International Journal of Radiation Oncology, Biology, Physics.

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy.

J. Sparano, L. Mauriac, D. Lebwohl, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane

J. Ajani, C. Bokemeyer, M. Shah, 2006, Investigational New Drugs.

Research and innovation in the development of everolimus for oncology

R. Motzer, H. Lane, T. O'reilly, 2011, Expert opinion on drug discovery.

Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.

H. Lane, D. Lebwohl, 2006, Seminars in oncology.

The T lymphocyte response to cytochrome c--II. Molecular characterization of a pigeon cytochrome c determinant recognized by proliferating T lymphocytes of the B10.A mouse.

E. Margoliash, L. Matis, D. Lebwohl, 1980, Molecular immunology.

5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.

C. Hudis, L. Norton, M. Theodoulou, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New developments in chemotherapy of advanced breast cancer.

D. Lebwohl, R. Canetta, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy

D. Lebwohl, T. Taran, M. Leung, 2019, Current Hematologic Malignancy Reports.

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.

Jürgen Hennig, Eric Masson, Yu-Yun Ho, 2005, European journal of cancer.

Taxol (paclitaxel) plus recombinant human granulocyte colony-stimulating factor in the treatment of metastatic breast cancer.

C. Hudis, L. Norton, J. Crown, 1994, Oncology.

Correcting Overall Survival for the Impact of Crossover Via a Rank-Preserving Structural Failure Time (RPSFT) Model in the RECORD-1 Trial of Everolimus in Metastatic Renal-Cell Carcinoma

M. Branson, D. Lebwohl, P. Korhonen, 2012, Journal of biopharmaceutical statistics.

respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Patients with acute myeloid leukemia and an activating mutation in FLT3

E. Estey, D. Neuberg, J. Griffin, 2013 .

Phase II trial of carboplatin and etoposide in metastatic breast cancer

C. Hudis, L. Norton, J. Crown, 1993, Cancer.

Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).

G. Hortobagyi, J. Baselga, H. Rugo, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.

K. Gelmon, J. Dancey, L. Seymour, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials.

F. Bretz, D. Lebwohl, L. Hampson, 2019, JCO precision oncology.

A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days

M. Ratain, E. Vokes, D. Lebwohl, 1999, Cancer Chemotherapy and Pharmacology.

PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.

Jennifer Hayes Clark, E. Estey, D. Neuberg, 2004, Annals of hematology.

Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC)

P. Kantoff, W. Oh, D. Lebwohl, 2004 .

A novel Bayesian dose-escalation phase Ib design investigating safety of combination of RAD001 with chemotherapy plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab

D. Lebwohl, T. Sahmoud, L. Vittori, 2008 .

New Indications of mTOR Inhibitors in Rare Tumors

D. Lebwohl, S. Stergiopoulos, G. Shah, 2016 .

Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC).

P. Kantoff, W. Oh, D. Lebwohl, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin chemotherapy in metastatic breast cancer: A National Cancer Institute of Canada clinical trials group study.

E. Eisenhauer, D. Lebwohl, T. Vandenberg, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen adminstration is associated with a high rate of treatment‐limiting symptoms in male breast cancer patients

D. Lebwohl, P. Borgen, T. Moredo Anelli, 1994 .

PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial.

Jennifer Hayes Clark, E. Estey, D. Neuberg, 2004, Annals of hematology.

Summary of results in patients with metastatic renal cell cancer (RCC) from phase I studies of RAD001 (everolimus).

J. Baselga, I. Judson, H. Burris, 2006, Journal of Clinical Oncology.

Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells

K J Cullen, N. Rosen, W. Miller, 1995, Journal of cellular physiology.

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

E. Estey, D. Neuberg, J. Griffin, 2004 .

Taxol plus recombinant human granulocyte-colony stimulating factor as initial and as salvage chemotherapy for metastatic breast cancer: a preliminary report.

J. Crown, D. Lebwohl, A. Seidman, 1993, Journal of the National Cancer Institute. Monographs.

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

D. Lebwohl, Ö. Anak, S. Saletan, 2013, Annals of the New York Academy of Sciences.

Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy

A. Harris, G. Folprecht, K. Gatter, 2011, Clinical Cancer Research.

Polylysine activates and alters the divalent cation requirements of the insulin receptor protein tyrosine kinase

D. Lebwohl, O. Rosen, David E. Lebwohl, 1988, FEBS letters.

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

M. Piccart, G. Hortobagyi, J. Baselga, 2014, Advances in Therapy.

Overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients corrected for crossover using inverse probability of censoring weights (IPCW) and rank preserving structural failure time (RPSFT) models: Two analyses from the RECORD-1 trial.

R. Motzer, D. Lebwohl, P. Korhonen, 2010 .

Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.

G. Hortobagyi, J. Baselga, H. Rugo, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.